Quest Diagnostics Inc. (NYSE:DGX) delivered a robust second quarter in 2025, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.
However, the diagnostic test provider flagged potential headwinds from ongoing tariffs and the significant financial impact if the Protecting Access to Medicare Act (PAMA) is not deferred, setting the stage for a watchful eye on legislative and trade developments.
